Startup profile · funding coverage
Telepatia AI funding, valuation and investors
AI-native clinical platform for Latin American hospitals — documentation and decision support.
Keep track of Telepatia AI
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$33M · June 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$33M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Telepatia builds an AI-native clinical platform for hospitals in Latin America, covering clinical documentation, decision support, and care protocol adherence. The company deployed across 25+ hospital systems reaching approximately 14 million patients within its first year of scaled rollout per a16z materials. In June 2026, Andreessen Horowitz led a $33M Series A bringing total funding to $42M. Telepatia targets regions with severe clinician shortages where AI-assisted documentation can recover physician time and standardize care pathways across facilities.
Why Telepatia AI is interesting
LATAM clinician shortages make AI scribe and protocol tools urgent — a16z-led $33M Series A deployed across 25+ hospital systems reaching 14M patients.
Product & use cases
Telepatia integrates with hospital EMRs to automate clinical note generation, surface decision-support alerts, and enforce protocol checklists — tuned for LATAM care settings.
- Physicians reducing documentation time with AI scribe features
- Hospital systems standardizing treatment protocols across sites
- Health networks extending specialist coverage via AI-assisted workflows
Key facts
- Series A (Jun 2026): $33M led by a16z; $42M total funding (a16z, MobiHealthNews)
- Deployed across 25+ hospital systems, ~14M patients reached (a16z)
- AI clinical documentation and decision support for LATAM
- Addresses clinician shortage with protocol adherence tools
Funding history (newest first)
Series A
2026-06 $33MSource: https://a16z.com/announcement/investing-in-telepatia/
Investors in our directory
Funds linked from Telepatia AI's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: LATAM-first deployment and 25+ health system references in under a year — faster hospital land grab than U.S.-centric scribe vendors.
Clinical AI scribes are hot in the U.S.; Telepatia bets LATAM hospital groups will adopt faster with fewer legacy IT constraints — regulatory and liability rules differ by country.
-
Nuance DAX (Microsoft) incumbent
Enterprise ambient documentation; U.S.-focused.
-
Abridge adjacent
AI medical scribe for U.S. health systems.
-
Local EMR vendors incumbent
Legacy hospital software without AI-native workflows.
Notable stories
- Telepatia hit 25 hospital systems and 14M patients in under a year — a16z's Series A thesis is that LATAM adoption curves beat U.S. scribe sales cycles (a16z announcement, 2026).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Telepatia AI's financing or category context.
FAQs about Telepatia AI
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.